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The tumour microenvironment harbours
ontogenically distinct dendritic cell populations
with opposing effects on tumour immunity
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Various steady state and inﬂamed tissues have been shown to contain a heterogeneous DC
population consisting of developmentally distinct subsets, including cDC1s, cDC2s and
monocyte-derived DCs, displaying differential functional specializations. The identiﬁcation of
functionally distinct tumour-associated DC (TADC) subpopulations could prove essential for
the understanding of basic TADC biology and for envisaging targeted immunotherapies. We
demonstrate that multiple mouse tumours as well as human tumours harbour ontogenically
discrete TADC subsets. Monocyte-derived TADCs are prominent in tumour antigen uptake,
but lack strong T-cell stimulatory capacity due to NO-mediated immunosuppression.
Pre-cDC-derived TADCs have lymph node migratory potential, whereby cDC1s efﬁciently
activate CD8þ Tcells and cDC2s induce Th17 cells. Mice vaccinated with cDC2s displayed a
reduced tumour growth accompanied by a reprogramming of pro-tumoural TAMs and a
reduction of MDSCs, while cDC1 vaccination strongly induces anti-tumour CTLs. Our data
might prove important for therapeutic interventions targeted at speciﬁc TADC subsets or
their precursors.
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D
endritic cells (DCs) are specialized antigen-presenting
cells, present in all tissues, that play a major role in
orchestrating immune responses1. The presence of
mature DCs in tumours has been correlated with a positive
prognosis in several tumour types2,3. However, multiple clinical
studies have indicated a defective functionality and scarcity of
mature DCs in tumours4–6. In addition, DCs seem to switch from
an immunostimulatory activation state driving anti-tumour
immunity in early stage tumours to an immunosuppressive
activation state at later stages7. The secretion of immuno-
suppressive factors by cancer cells has been proposed to be
implicated in the control of DC differentiation, maturation and
function4,8. In addition, tumour-associated DCs (TADCs) may
favour tumour progression by mediating genomic damage,
supporting neovascularization and stimulating cancerous cell
growth and spreading4,9,10, features that may be attributed to the
existence of distinct TADC populations10.
Although not much is known about DC heterogeneity in
tumours, DCs isolated from various steady-state and inﬂamed
tissues have been shown to represent a heterogeneous population
consisting of developmentally distinct DC subsets11–13, including
cDC1s (CD8aþ -like or CD103þ conventional DCs), cDC2s
(CD11bþ -like cDCs), plasmacytoid DCs (pDCs) and so-called
monocyte-derived DCs (Mo-DCs)12,14,15. Notably, distinct
DC classiﬁcation systems and nomenclatures have been used.
Throughout this manuscript, we employ the ontogeny-based
classiﬁcation/nomenclature as proposed by Guilliams et al15.
cDCs arise from bone marrow-derived pre-cDC precursors in an
Flt3L-dependent fashion16, are maintained under homeostatic
conditions by (granulocyte–macrophage colony-stimulating
factor receptor) GM-CSFR signalling17 and differentiate into
cDC1s and cDC2s under the control of BATF3, ID2 and IRF8 or
RELB, ZEB2 and IRF4, respectively, while Mo-DCs differentiate
from Ly6Chi monocytes which exit the bone marrow in a CCR2-
dependent manner and were reported not to require GM-CSFR
signalling for their in vivo differentiation17–19. Importantly,
transcriptomic analysis of mouse and human DC subsets
revealed that human CD141 (BDCA3)þ DCs are related
to mouse cDC1s, whereas human CD1c (BDCA1)þ DCs are
more related to mouse cDC2s (ref. 20). Human CD141þ DCs
express Batf3 and IRF8 and lack expression of IRF4, akin to
mouse cDC1s. Moreover, the differentiation of human
haematopoietic progenitors into CD141þ DCs occurs only
when Flt3L is added to the cultures, and inhibition of Batf3 in
these cultures abolishes the differentiation of CD141þ DCs but
not of CD1cþ DCs, suggesting that CD141þ DCs are indeed
developmentally related to mouse cDC1s.
Importantly, DCs of distinct cellular origin have been shown to
display a differential functional specialization. While cDC1s are
specialized in the induction of cytotoxic T-cell (CTL) responses,
cDC2s have been shown to excel at the induction of Th17 or Th2
responses13,21–23. Although the migratory potential of Mo-DCs is
debated, they have been proposed to reactivate effector T cells in
inﬂamed tissues13. Whether the various functions ascribed to
TADCs are in fact performed by distinct DC subsets is unknown,
but the recent elegant report of cDC1 presence in tumours24
emphasizes that the tumour tissue may, like any other tissue, be
populated by DCs with distinct developmental origin and
possibly a differential functional specialization. As a matter of
fact, subpopulations of tumour-associated macrophages (TAMs)
with distinct functions have been identiﬁed25,26. Here, we aimed
to investigate the generation and function of ontogenically
distinct DC populations and to assess their potential for
inducing anti-tumour responses. Our data unveil the
complexity of the TADC compartment, which is for the ﬁrst
time demonstrated to consist of both pre-cDC and monocyte-
derived DC subsets in tumours, and might prove important for
therapeutic interventions targeted at speciﬁc TADC subsets or
their precursors.
Results
Distinct TADC subsets derive from different precursors.
To delineate the relative abundance of distinct tumour-associated
DC (TADC) populations in solid tumours, we ﬁrst employed the
3LL-R Lewis Lung Carcinoma model, which is known to be
strongly inﬁltrated by myeloid cells26. These tumours contain a
sizeable population of CD3neg CD19neg Ly6Gneg CD11chi MHC-
IIhi TADCs (Fig. 1a). Earlier studies characterized distinct DC
populations based on their differential expression of CD24,
CD11b, Ly6C and CD64 (ref. 27). Using this approach, three
discrete TADC subsets were clearly distinguishable (Fig. 1a):
Ly6Clo CD64lo CD24þ CD11blo conventional TADCs (cDC1s,
gate 1), Ly6Clo CD64lo CD24int-lo CD11bþ conventional TADCs
(cDC2s, gate 2) and Ly6Chi CD64hi CD24int CD11bþ monocyte-
derived TADCs (Mo-DCs, gate 3). This situation is similar to
what has been reported in several non-cancerous tissues12.
We further assessed the origin of TADC subsets by adoptive
transfer of pre-cDCs and monocytes in 3LL-R tumour-bearing
mice. When adoptively transferring sorted CD45.2þ B220
CD11cþ Sirpaint CellTraceþ bone marrow pre-cDC precur-
sors28 in 3LL-R tumour-bearing CD45.1þ recipient mice, only
Ly6Clo CD64lo CD24þ CD11blo and Ly6Clo CD64lo CD24int-lo
CD11bþ cells could be retrieved from tumours after 72 h
(Fig. 1b). Importantly, none of the transferred pre-cDC
precursors differentiated into CD64hi CD11bþ cells during this
time span. In contrast, transferred CD45.2þ CD11bþ Ly6G
Ly6Cþ MHC-II CellTraceþ bone marrow monocytes were all
retrieved as CD64hi CD11bþ cells within the TADC gate. Note
that relatively low amounts of CD45.2þ Mo-DCs were retrieved
from tumours since most transferred monocytes gave rise
to MHC-IIlow and MHC-IIhigh TAMs, which make up the bulk
of monocyte-derived cells in 3LL-R tumours (Supplementary
Fig. 1). Altogether these data indicate that Ly6Clo CD64lo CD24þ
CD11blo, Ly6Clo CD64lo CD24int-lo CD11bþ and CD64hi
CD11bþ cells represent cDC1, cDC2 and Mo-DCs, respectively.
Corroborating the adoptive transfer experiments, 3LL-R
tumours grown in CCR2-deﬁcient mice, in which the egression
of monocytes from the bone marrow is strongly reduced18,
showed almost complete absence of the Mo-DC subset while
cDC1s and cDC2s were unaffected (Fig. 1c). In line with their
cDC ontogeny, the amounts of tumour-associated cDC1s and
cDC2s were strongly reduced in both Flt3L-KO and GM-CSFR-
KO mice, showing their dependence on both Flt3L and GM-CSF
(Fig. 1c). The residual presence of cDC2s in tumours in both KO
strains suggests that their generation and/or survival may depend
on the simultaneous functioning of (other) haematopoietic
growth factors in the tumour microenvironment29. Importantly,
also Mo-DCs were heavily affected by the absence of Flt3L and
the inability to respond to GM-CSF. Whether this drop in
Mo-DCs reﬂects a direct effect of Flt3L and/or GM-CSF on
Mo-DC differentiation/maintenance, or whether the loss of cDC
subsets in these KO tumours inﬂuences the development of
Mo-DCs, is not clear at present.
Following the fate mapping experiments, we further character-
ized the TADC subsets for markers that were reported to
associate with different DC populations. In this respect, the need
for IRF8 and IRF4 in the development of cDC1s and cDC2s,
respectively, has been established30. Intracellular staining for
these transcription factors conﬁrmed the higher expression
of IRF4 in cDC2s and of IRF8 in cDC1s (Fig. 1d). Interestingly,
Mo-DCs appeared to contain relatively high levels of IRF4 and
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Figure 1 | Origin of different TADC subpopulations. (a) TADCs of 12-day-old 3LL-R tumours were subdivided into (1). CD64neg CD24pos CD11blo cDC1s, (2).
CD64neg CD24neg CD11bpos Ly6Clo cDC2s and (3). CD64pos CD24int CD11bpos Ly6Chi Mo-DCs. For each subset, forward scatter versus side scatter plots
are shown. Results are representative of four independent experiments with nZ4. (b) Pre-cDCs (B220CD11cþSirpaint) and monocyte precursors
(CD11bþLy6G Ly6CþMHC-II ) were sorted from CD45.2þ bone marrow and labelled with CellTrace. Either 4 105 pre-cDCs or 1 106 monocytes were
adoptively transferred (IV) to CD45.1 7-day-old 3LL-R tumour-bearing recipient mice. Three days later, tumours were processed and transferred cells were gated
based on their CD45.1CD45.2þCellTraceþ phenotype. Results are representative of two independent experiments with n¼ 2–4. (c) 3LL-R tumours were grown
for 12 days in WT, CCR2-KO, Flt3L-KO and GM-CSFR KO mice. The percentage of each TADC subpopulation within the total tumour single-cell suspension was
determined. Results are representative of two independent experiments with n¼ 6. Statistical analysis by two-way ANOVA. *Po0.05; **Po0.01; ***Po0.001;
****Po0.0001. (d) Single-cell suspensions of 12-day-old 3LL-R tumours were stained for the indicated markers and histogram overlays are shown for the TADC
subsets. Black line¼ expression of the indicated marker; shaded histogram¼ isotype control. DMFI±s.e.m. are indicated and represent (MFI markerMFI control).
Results are representative of two independent experiments with nZ4. Statistical analysis by one-way ANOVA. *Po0.05; **Po0.01; ***Po0.001; ****Po0.0001.
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low levels of IRF8. In agreement with their monocytic origin, the
Mo-DCs expressed high levels of FceR (Fig. 1d), previously
associated with monocyte-derived DCs13. Furthermore, the Mo-
DC population was also the only subset expressing the
macrophage-related marker MerTK27,31. Both CD103 and the
cross-presentation related marker XCR1 seem to be uniquely
expressed on the cDC1 subset, whereas SIRPa expression
was limited to the Mo-DC and cDC2 subsets (Fig. 1d). Finally,
DEC205 is expressed on all TADC subsets with
Mo-DC4cDC14cDC2 (Fig. 1d).
Distinct TADC subsets are present in multiple tumour types.
We then assessed the presence of TADC subsets in several
transplantable mouse tumour models of various histological ori-
gins and distinct genetic backgrounds and in the spontaneous
MMTV-PyMT breast carcinoma model. Single-cell suspensions
of subcutaneously growing LLC-OVA lung carcinoma tumours,
their fast progressing 3LL-R and slowly progressing 3LL-S sub-
clones32, MC38 colon carcinoma, B16 melanoma and T241
ﬁbrosarcoma, as well as 3LL-R tumours orthotopically growing in
the lung parenchyma and MC38 orthotopically growing in the
rectum (all in C57Bl/6 background) contained small, but clearly
identiﬁable CD11chi MHC-IIhi TADC fractions (Fig. 2a). TADCs
were also retrieved from MMTV-PyMT mammary tumours in
the FVB background (Fig. 2a).
When comparing the DC content of similarly sized tumours,
the cDC1s were the rarest subset in all investigated models,
whereas the cDC2s were always well represented (between 30.1%
and 75.7% of all TADCs depending on the model) (Fig. 2b). The
greatest variability was seen among the Mo-DCs, which were only
poorly present in 3LL-R and T241 tumours, but form a sizeable
population in LLC-OVA, MMTV-PyMT, 3LL-S, MC38 and B16
tumours, being even the dominant TADC population in the latter
three models. Interestingly, the TADC content of subcutaneously
versus orthotopically grown 3LL-R or MC38 tumours is very
comparable, suggesting that the tumour microenvironment rather
than the surrounding tissue dictates TADC heterogeneity.
Notably, tumour models with a high Mo-DC content also
harbour relatively more M1-like MHC-IIhigh TAMs as compared
with their M2-like MHC-IIlow counterparts (high MHC-IIhigh/
MHC-IIlow TAM ratio) (Fig. 2c), suggesting that the micro-
environment in these tumours favours the differentiation of
inﬁltrating monocytes towards these MHC-IIhigh macrophages
and DCs. Of note, MC38 tumours, which also contain a large Mo-
DC population, contain a single TAM population displaying a
mixed M1-like and M2-like phenotype (Fig. 2c). The correlation
between Mo-DCs and MHC-IIhigh TAM presence is maintained
within the same tumour model, whereby an underrepresentation
of MHC-IIhigh TAMs and a gradual accumulation of MHC-IIlow
TAMs in the course of tumour growth is paralleled by a reduced
percentage of Mo-DCs, as illustrated by the 3LL-R model (Fig. 2d
and Supplementary Fig. 2A). However, the total percentage of
3LL-R-inﬁltrating TADCs increases during tumour growth
(Fig. 2d). In contrast, 3LL-S tumours are invariably dominated
by MHC-IIhigh TAMs (within the TAM compartment) and
Mo-DCs (within the TADC compartment) throughout tumour
growth and the percentage of TADCs did not change
(Supplementary Fig. 2B,C).
The distinct TADC subsets are also present in human tumours.
To translate our original ﬁndings to the human situation, the
presence of distinct TADC subpopulations was assessed in fresh
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Figure 2 | Several tumour types are inﬁltrated with distinct TADC subsets. (a) TADCs were gated as doubletsneg live (AQUAneg) Ly6Gneg CD3neg
CD19neg CD11cpos MHC-IIpos cells in single-cell suspensions of 20-day-old subcutaneous (s.c.) LLC-OVA lung carcinoma, 12-day-old s.c. 3LL-R lung
carcinoma, 6-day-old 3LL-R orthotopically injected lung carcinoma, 35-day-old s.c. 3LL-S lung carcinoma, 17-day-old s.c. MC38 colon carcinoma,
28-day-old MC38 orthotopically injected colon carcinoma, 20-day-old B16-OVA s.c. melanoma, 20-day-old T241 s.c. ﬁbrosarcoma and 16-week-old
spontaneously grown MMTV-PyMTmammary carcinoma with tumours of similar volumes. (b) The percentage of each TADC subset within the total TADC
population was determined for indicated tumours of similar volumes. (c) The percentage of each TAM subset within the total CD11bþ Ly6G population
was determined for indicated tumours of similar volumes. (a–c) Graphs show mean±s.e.m. Results are representative of two independent experiments
with n¼ 3–10. (d) Amount of total TADCs (d, left panel) and TADC subsets (d, right panel) was assessed in single-cell suspensions of 7-, 11- and 15-day-
old 3LL-R tumours. Graphs show mean±s.e.m. Results are representative of three independent experiments with nZ4. Statistical analysis by one-way
ANOVA. *Po0.05; **Po0.01; ***Po0.001; ****Po0.0001.
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tumour biopsies of lung and colorectal cancer patients. Small
amounts of CD16 CD11cþ HLA-DRþ TADCs were retrieved
from human tumours (Fig. 3a,b and Supplementary Fig. 3A).
Importantly, this TADC compartment encompassed three
distinct subsets, highly reminiscent of the murine TADC subsets.
Human TADCs contained a BDCA2 BDCA1 IRF8þ
CD14 CD11blow cDC1 population, which also expressed the
other commonly used cDC1 marker BDCA3 (Supplementary
Fig. 3B), and a BDCA2 IRF8- BDCA1þ TADC fraction, which
consisted of two subsets with differential CD14 and CD11b
expression (Fig. 3a,c). As previously suggested33, these consist of a
CD14 CD11bþ cDC2 population and a CD14þ CD11bhigh
DC population, analogous to murine Mo-DCs. Of note, no
BDCA2þ plasmacytoid DCs could be retrieved.
Mo-DCs have the highest inherent antigen uptake capacity.
Although the induction of potent antitumour immune responses
has been attributed to DCs in some reports2,34, TADCs have also
been described as tolerogenic or immunosuppressive cells with
impaired antigen presenting, T-cell stimulating and migratory
capacities, enabling tumour immune escape4,10,34,35. Hence,
it could be postulated that distinct TADC subsets exert
different functions. In ﬁrst instance, we investigated the antigen
uptake, processing and presenting capacities by the three distinct
TADC populations.
Their inherent phagocytic capacity was tested in vitro by
adding ﬂuorescent latex beads to 3LL-R tumour single-cell
suspensions at 37 C (active phagocytosis) or at 4 C
(Supplementary Fig. 4A). All TADC subsets were able to ingest
latex beads at 37 C. However, when compared with the total
TADC population, the proportion of cells within the latexþ
TADC population only increased for the Mo-DC subset,
signifying that this population was more phagocytic than both
cDC types (Supplementary Fig. 4B). Interestingly, when perform-
ing an in vivo phagocytosis assay by injecting ﬂuorescent latex
beads intravenously into tumour-bearing mice 2 h before
removing the tumour, the Mo-DCs were again overrepresented
within the latexþ population, corroborating their superior
phagocytic capacity in vivo (Supplementary Fig. 4C).
The uptake of relatively large beads by phagocytosis is
mechanistically distinct from the uptake of protein antigens,
such as ovalbumin (OVA). Adding ﬂuorescently labelled OVA to
3LL-R tumour single-cell suspensions for 15min at 4 and 37 C
(active Ag uptake) revealed that all TADC subsets were able to
ingest OVA at 37 C (Fig. 4a), but that Mo-DCs again showed a
higher Ag uptake capacity compared with both cDC types
(Fig. 4b). To further test OVA processing by the different TADC
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Figure 3 | The presence of distinct TADC subsets can be recapitulated in human tumours. (a) Human NSCLC tumour biopsies were pre-gated on
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subsets, 3LL-R tumour single-cell suspensions were incubated
with DQ-OVA for 15min, allowing antigen uptake. Following
thorough washing, intracellular processing was assessed at
different time intervals using the ﬂuorescence of cleaved DQ-
OVA as a readout. The vast majority of Mo-DCs rapidly
incorporated and processed DQ-OVA (62.7±3.5% of ﬂuorescent
cells after 15min), while hardly any processing had occurred in
cDC1s and cDC2s at this early time point (Fig. 4c). Gradually
more cDCs processed DQ-OVA, with a slightly higher efﬁciency
for cDC2s compared with cDC1s (reaching 30.5±11.6% versus
7.8±4.6% ﬂuorescent cells after 45min, respectively). Together,
these data illustrate the competitive advantage of Mo-DCs for
antigen uptake, leading to subsequent antigen processing.
Finally, we assessed whether TADCs were capable of proces-
sing OVA and cross-presenting its immunodominant CTL
epitope (SIINFEKL) in vivo, by staining freshly isolated TADC
subsets from LLC-OVA tumours with an mAb speciﬁc for
H-2Kb/SIINFEKL complexes. Mo-DCs showed the highest
expression of these complexes, indicative of a superior antigen
uptake and/or processing in the tumour microenvironment
(Fig. 4d).
cDC2s induce a Th17 CD4þ T-cell phenotype. We then eval-
uated the capacity of TADC subsets to activate naive T cells. In
this regard, the expression of activating and inhibitory T-cell
costimulatory molecules, such as CD80, CD86, PDL1 and PDL2
was very high on all TADC populations (Supplementary Fig. 5A).
First, the intrinsic antigen-presenting capacity of TADC
subsets, irrespective of their antigen uptake and processing
capacity, was assessed in a classic mixed leukocyte reaction
(MLR). All C57Bl/6 TADC subsets could activate naive Balb/c
CD4þ and CD8þ T-cell proliferation, at least to the same
extent as the control splenic CD11chiMHC-IIhiB220Ly6C
cDC population (Supplementary Fig. 5B,C). Interestingly, the
cDC2s showed the highest intrinsic antigen-presenting capacity
towards both CD4þ and CD8þ T cells.
To incorporate the effect of a differential in vivo antigen uptake
and processing capacity in our assay, TADCs were sorted from
LLC-OVA tumours and immediately co-cultured with carboxy-
ﬂuorescein succinimidyl ester (CFSE)-labelled TCR transgenic
CD8þ OT-I T cells or CD4þ OT-II T cells without additional
ex vivo Ag loading or stimulation. At a DC/OT-I ratio of 1/10, only
the two cDC subsets could effectively induce CD8þ T-cell
proliferation, hence demonstrating their in vivo immunostimula-
tory phenotype, whereby the cDC1s were considerably more potent
(Fig. 5a). Also in the case of CD4þ T cells, only the cDC subsets
were able to induce T-cell proliferation at a DC/OT-II ratio of 1/10,
with now cDC2s being most efﬁcient (Fig. 5b). Notably, within the
timeframe of the experiment (3 days of stimulation), hardly any
interferon-g (IFN-g) and interleukin-4 (IL-4) (Supplementary
Fig. 5D) and no IL-13 (data not shown) could be detected in the
supernatant of OT-II/TADC co-cultures, illustrating the lack of
Th1 and Th2 induction by the TADC subsets.
Interestingly however, cDC2s induced the differentiation of a
Th17 population, as demonstrated by the upregulation of
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RORgt—but not T-bet, GATA3 or FoxP3—in a population of
OT-II cells, and the secretion of IL-17 in the supernatant
(Fig. 5c,d and Supplementary Fig. 5E). Neither RORgtþ T cells
nor IL-17 production were found in any other condition. The
induction of Th17 may result from the inherently high
production of Th17-inducing cytokines, such as IL-23, IL-1b
and IL-6, by cDC2s (Fig. 5e). It should be noted that Mo-DCs
secrete even higher levels of IL-1b and IL-6 but have a
signiﬁcantly lower IL-23 production, possibly explaining their
lack of Th17-inducing capacity.
We next compared the T-cell activating capacity of tumour-
associated cDC1s and cDC2s with cDC1 and cDC2 subsets from
naive spleens (gating strategy in Supplementary Fig. 6A), which
also expressed high levels of the costimulatory molecules CD80,
CD86, PDL1 and PDL2 (Supplementary Fig. 6B). TADCs sorted
from LLC tumours or naive splenic cDCs were co-cultured with
CellTrace-labelled TCR transgenic CD8þ OT-I T cells or CD4þ
OT-II T cells in the presence of OVA. At a DC/OT-I ratio of 1/10,
tumour-derived cDC subsets induced CD8þ OT-I T-cell
proliferation to the same extent as their splenic cDC counterparts
(Supplementary Fig. 6C). Interestingly, in the case of CD4þ OT-
II T-cells, the highest proliferation was measured when T cells
were co-cultured with tumour-derived cDC2s (Supplementary
Fig. 6D). Moreover, tumour-derived cDC2s produced signiﬁ-
cantly higher levels of the Th17-inducing cytokine IL-23 than
splenic cDC2s in these co-cultures (Supplementary Fig. 6E).
Consequently, high levels of IL-17 could only be detected in the
co-cultures containing tumour-derived cDC2s, further illustrating
the unique Th17 inducing capacity of these cells (Supplementary
Fig. 6E).
Mo-DCs display an immune suppressive TIP-DC phenotype.
Tumour-associated Mo-DCs were consistently less efﬁcient in
activating naive antigen-speciﬁc T cells, in spite of their higher
antigen uptake and processing capacity. Therefore, we wondered
whether the Mo-DCs displayed features that could annihilate
their T-cell stimulatory functions. We noted that Mo-DCs co-
expressed high levels of tumour necrosis factor-a (TNF-a) and
inducible nitric oxide synthase (iNOS) compared with both cDC
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subsets and hence displayed a phenotype reminiscent of inﬂam-
matory TNF-a and iNOS producing DCs (TIP-DCs) (Fig. 6a and
Supplementary Fig. 7A). Moreover, these cells produced the
highest levels of the inﬂammatory cytokines IL-6 and IL-1b, the
monocyte and neutrophil attracting chemokines CCL2, CCL4
and CXCL1 and reactive oxygen species, such as the mitochon-
drial superoxide anion, of all TADC populations (Figs 5e and 6a
and Supplementary Fig. 7B). In addition, they displayed the
highest IL-10/IL-12 balance (Fig. 6b), a feature that is linked with
a less immunogenic DC phenotype.
To directly assess whether tumour-derived Mo-DCs have the
capacity to suppress T-cell responses, we in ﬁrst instance
polyclonally stimulated naive syngeneic splenocytes in the presence
of increasing amounts of Mo-DCs. Mo-DCs dose-dependently
suppressed T-cell proliferation (Fig. 6c), while cDC2s sorted from
tumours or splenic cDCs did not (Supplementary Fig. 7C).
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Moreover, Mo-DCs were not able to induce OVA-stimulated OT-
II T-cell proliferation at any concentration tested and strongly
inhibited, in a concentration dependent way, cDC2-driven OVA-
stimulated OT-II T-cell proliferation (Fig. 6d).
Importantly, higher iNOS expression might result in a higher
NO production, which is reported to be a potential T-cell
suppressive molecule36,37. Mo-DCs sorted from LLC-OVA
tumours were co-cultured with polyclonally activated
splenocytes in the presence of the iNOS inhibitor L-NMMA
(Fig. 6e). T-cell proliferation was signiﬁcantly enhanced under
these conditions, demonstrating an active NO-mediated T-cell
suppressive activity by Mo-DCs. The TIP-DC phenotype,
including iNOS expression, was shown before to depend on
IFN-g38. The addition of blocking anti-IFN-g antibodies to the
Mo-DC/SPC cultures indeed also increased T-cell proliferation,
although to a lesser extent than iNOS inhibition. Similar ﬁndings
were obtained upon co-culture of LLC-OVA-derived Mo-DC
with CFSE-labelled CD8þ OT-I T cells (Supplementary Fig. 7D).
Hence, Mo-DCs display an immune suppressive TIP-DC
phenotype that precludes the potent activation of T cells.
Both tumour cDC subsets migrate to draining lymph nodes.
Tumour-associated cDCs possessed T-cell stimulating capacity,
so we next wondered whether these cells were capable of
migrating to the tumour-draining lymph nodes (tdLNs) and
present tumour antigen. CCR7 expression, which is a prerequisite
for DC migration to lymph nodes (LNs), was only present on the
cDC subsets but not on Mo-DCs (Fig. 7a).
In the axillary and inguinal tdLNs (draining LNs for a
subcutaneous tumour in the ﬂank of the animal), cDC1 and cDC2
subsets, but not Mo-DCs, were present within the migratory DC
population (Supplementary Fig. 8A), conﬁrming the non-
migratory character of Mo-DCs. Migratory and resident DCs
were discriminated based on CD11c and MHC-II expression, as
previously reported39,40. To assess whether these cDCs present
tumour antigen, they were sorted from tdLNs of LLC-OVA
tumour-bearing mice and co-cultured with CFSE-labelled CD8þ
OT-I T cells or CD4þ OT-II T cells. Importantly, care was taken
that no OVAþ cancer cells were present in the tdLN at the time
of cDC sorting, as illustrated by the absence of OVA mRNA
(Supplementary Fig. 8B). Migratory cDC1s, but not cDC2s,
strongly stimulated OT-I proliferation (Fig. 7b), suggesting
in vivo migration of SIINFEKL-loaded cDC1s from the tumour
to the tdLNs. Notably, both resident cDC subsets were largely
incapable of inducing OT-I T-cell proliferation (Fig. 7b).
By contrast, both migratory cDC1s and cDC2s could stimulate
OT-II T-cell proliferation (Fig. 7c). Unexpectedly, also the
resident cDC1s and cDC2s induced OT-II proliferation
(Fig. 7c), suggesting that migratory tumour-associated cDCs
could transfer antigen to LN-resident cDCs populations for
effective OT-II priming. Notably, similar to the tumour-
associated cDC2s, tdLN migratory and resident cDC2s also
induced RORgt in a fraction of the OT-II T cells (Fig. 7d).
Activated T cells may migrate from the tdLNs to the primary
tumour where they are confronted with TADCs. To assess
whether tumour-resident DCs inﬂuence the activity of
Ag-experienced T cells, we co-cultured TADCs from LLC-OVA
tumours with sorted CD4þ or CD8þ T cells from the tdLNs of
12-day-old LLC-OVA-bearing mice. Interestingly, cDC2s were
signiﬁcantly better in triggering T-cell proliferation of in vivo
primed T cells than Mo-DCs (Supplementary Fig. 8C).
cDC2s have beneﬁcial effects when used for vaccination.
Finally, to assess whether tumour-derived DC subsets could be
used to elicit relevant immune memory responses in cancer, we
set up vaccination experiments as depicted in Fig. 8a. Impor-
tantly, the sorted TADC subsets used for the vaccination
experiments were not ex vivo stimulated with cytokines, nor
loaded with tumour antigen. Since Mo-DCs did not display LN
migratory capacities and harboured immunosuppressive capa-
cities (Fig. 6c,d), we decided to focus on the potential prophylactic
effects of the cDC subsets.
Remarkably, upon challenge with LLC-OVA, only the cDC2-
vaccinated mice had a signiﬁcantly reduced tumour growth rate
and weight compared with the non-vaccinated mice (Fig. 8b,c).
However, a similar, though non-signiﬁcant, trend was seen in the
cDC1-vaccinated cohort (Fig. 8b). As expected, tumour growth in
OVA-vaccinated mice was strongly retarded or inhibited. Slower
tumour growth correlated with a slightly increased presence of
CD8þ T cells in tumours of both vaccinated cohorts, which,
however, did not reach the signiﬁcantly higher levels seen in the
OVA-vaccinated mice (Supplementary Fig. 9A). Remarkably,
using H2Kb/SIINFEKL dextramer staining, the proportion of
tumour antigen-speciﬁc CD8þ T cells within the total CD8þ
T-cell population was signiﬁcantly increased in OVA-vaccinated
mice and a trend was visible in cDC1-vaccinated, but not in
cDC2-vaccinated mice (Supplementary Fig. 9B). These data are in
line with the superior CTL-stimulatory capacity of cDC1s, and
suggest that the stronger anti-tumour effect of cDC2 vaccination
is mediated by other changes in the tumour microenvironment.
In this respect, tumour- or tdLN-derived cDC2s, but not
cDC1s, were shown to stimulate Th17 cells in vitro (Figs 5c and
7d). In line with these data, the percentage of RORgtþ CD4þ
tumour-inﬁltrating lymphocytes (TILs) was only signiﬁcantly
increased in tumours from cDC2-vaccinated mice, without an
increase in the overall proportion of CD4þ T cells (Fig. 8d and
Supplementary Fig. 9C). No changes could be observed in the
amount of Foxp3þ Treg, T-betþ Th1 or GATA3þ Th2 CD4þ
TIL after vaccination, in any condition (Supplementary Fig. 9D–
F). Th17 cells were crucially involved in the anti-tumour effect of
cDC2 vaccination as this effect was totally abrogated in IL-23p19-
deﬁcient mice, which lack Th17 cells41 (Supplementary Figs 8E
and 10B). Accordingly, CD4þ T-cell depletion reversed
the cDC2-mediated protection (Supplementary Fig. S10A–C).
This is remarkable, since CD4þ T-cell depletion lowers tumour
growth in non-vaccinated mice, indicating that cDC2 vaccination
switches the CD4þ T-cell pool from mainly pro-tumoral to
mainly anti-tumoral. Notably, also CD8þ T-cell depletion partly
reversed the cDC2 vaccination effect (Supplementary
Fig. 10A,B,D), which is in accordance with the enhanced
activation state (as shown by enhanced IFNg production) by
these cells in tumours from vaccinated versus non-vaccinated
mice (Supplementary Fig. 10E). Depleting NK and NKT cells with
an anti-NK1.1 mAb did not inﬂuence tumour growth
(Supplementary Fig. 11A–C), despite a slight but signiﬁcant
increase in the NK (but not NKT) cell numbers (Supplementary
Fig. 11D). However, IFNg production by NK cells was unaffected
by cDC2 vaccination (Supplementary Fig. 11E).
In multiple tumour models, including LLC, tumour growth is
not only regulated by TILs, but also by the phenotype of tumour-
associated myeloid cells such as myeloid-derived suppressor cells
(MDSCs) and TAMs. Interestingly, the presence of CD11bhi
Ly6Chi MHC-IIneg Ly6Gneg monocytic cells and CD11bhi Ly6Cint
MHC-IIneg Ly6Ghi granulocytic cells is signiﬁcantly reduced in
tumours of cDC2-vaccinated mice as compared with non-
vaccinated and cDC1-vaccinated cohorts (Fig. 9a,b). To assess
whether these cells possess T-cell suppressive capacity, which
would classify them as monocytic and granulocytic MDSCs, they
were FACS sorted from tumour single-cell suspensions and added
at different ratios to polyclonally stimulated splenocytes. As
shown in Fig. 9c, these cells strongly suppress T-cell proliferation.
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Hence, cDC2 vaccination strongly reduces the presence of
MDSCs in tumours. Also M2-oriented TAMs promote tumour
progression. Overall CD11bhi Ly6Clo Ly6Gneg TAM numbers
only showed a trend towards a reduction in cDC2-vaccinated
mice (Fig. 9d). Importantly, within the TAM compartment, cDC2
vaccination caused a shift towards more M1-like MHC-IIhigh
TAMs (i.e. a lower MHC-IIlow/MHC-IIhigh TAM ratio)
(Fig. 9e,f). In addition, these MHC-IIhigh TAM had a more
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pronounced M1 phenotype as compared with those from non-
vaccinated animals, as evidenced by a further upregulated
expression of M1-associated genes, while most M2-associated
genes (except for Mmp9) did not signiﬁcantly change (Fig. 9g).
Notably, the few remaining MHC-IIlow TAMs from cDC2-
vaccinated mice also altered their M1 gene expression proﬁle,
with some genes being upregulated (Il1b, Ptgs2, Il12p40) and
others downregulated (Tnf, Nos2). M2 genes in these cells
remained mostly unchanged. Overall, these data show that the
myeloid compartment of LLC-OVA tumours from cDC2-
vaccinated mice is dominated by strongly M1-oriented TAMs.
Finally, we turned to the B16-OVA tumour model, in which
TAMs are present in very low numbers and are mainly M1-like
MHC-IIhigh polarized (Fig. 2c). In this model, antitumour effects
are more likely to be directly mediated by cytotoxic T cells
without an overt interference of tumour-inﬁltrating myeloid cells.
Indeed, vaccination with cDC1s isolated from LLC-OVA tumours
conferred a better protection than cDC2 vaccination (Fig. 10a),
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(a). For all experiments, results are representative of two independent experiments with n¼4–15 tumours. (e) Growth curve of LLC-OVA tumours after
vaccination with LLC-OVA derived cDC2s in WT or IL-23p19 KO mice. n¼8. Statistical analysis by one-way ANOVA. *Po0.05; **Po0.01; ***Po0.001;
****Po0.0001.
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Figure 9 | cDC2 vaccination reduces the MDSC inﬁltrate and reprograms TAMs from a protumoral M2-like to an M1-like phenotype. (a,b) Percentages
of Mo-MDSCs (a) and G-MDSCs (b) in LLC-OVA tumours after vaccination with LLC-OVATADC subsets following the protocol depicted in Fig. 8a. Results
are representative of two independent experiments with n¼4–15 tumours. Statistical analysis by one-way ANOVA. *Po0.05. (c) CD11bþ Ly6Chi Ly6G
Mo-MDSCs and CD11bþ Ly6Cint Ly6Gþ G-MDSCs were sorted from 12-day-old 3LL-R tumour single-cell suspensions and added at different ratios to anti-
CD3-stimulated splenocytes during 42 h and the proliferation T cells was measured via 3H-thymidine incorporation (c.p.m.). Results are representative of
three independent experiments with n¼ pool of 6 tumours. (d,e) Percentages of CD11bþ Ly6Gþ Ly6C TAMs (d) and the ratio of M2-like MHC-IIlow
TAMs/M1-like MHC-IIhigh TAMs (e) in LLC-OVA tumours after vaccination with LLC-OVATADC subsets following the protocol depicted in Fig. 8a. Results
are representative of two independent experiments with n¼4–15 tumours. Statistical analysis by one-way ANOVA. ***Po0.001. (f) Representative plot of
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(3) MHC-IIhigh TAMs. (g) Expression of indicated M1 and M2 associated genes in sorted MHC-IIlow and MHC-IIhigh TAM subsets of LLC-OVA
tumour-bearing mice vaccinated with cDC2 or HBSS was assessed using qRT-PCR. The expression was normalized based on the S12 housekeeping gene.
n¼ pool of 6 tumours. Statistical analysis by one-way ANOVA. *Po0.05; **Po0.01; ***Po0.001; ****Po0.0001.
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which correlated with a signiﬁcantly augmented inﬁltration of
CD8þ T cells in the former (Fig. 10b). Hence, depending on the
role of TAMs or TILs in tumour immunity, different tumour-
derived conventional TADC subsets could be exploited to develop
personalized DC adoptive immunotherapies.
Discussion
DCs are a heterogeneous population of cells and the coexistence
of developmentally and functionally distinct DC subsets
was reported in different organs, such as the skin, intestine and
lung11–13. Using precursor transfer experiments and Flt3L- and
CCR2-deﬁcient mice, we demonstrated for the ﬁrst time the
coexistence of three developmentally distinct TADC subsets:
pre-cDC-derived cDC1s, pre-cDC-derived cDC2s and monocyte-
derived Mo-DCs. The dissection of MHC-IIhigh CD11cþ
CD11bþ cells in cDC2s and Mo-DCs might explain the slight
expression of the monocyte/macrophage related markers
CD64 and MerTK in the ontogenically mixed CD11bþ TADC
population described by Broz et al.24
Moreover, using markers conﬁrmed by previously published
transcriptome analysis deﬁning human inﬂammatory monocyte
derived DCs33, the coexistence of cDC1s, cDC2s and Mo-DCs
was suggested in freshly isolated tumour biopsies of human lung
and colorectal cancer patients, indicating the therapeutic
relevance of dissecting the DC compartment in tumours.
Since TAMs make up the bulk of the monocyte-derived
intratumoral cells, the question arises which microenvironmental
cues instruct a monocyte to become a macrophage-like or a
DC-like cell. In this context, it is interesting to note that tumours
containing higher amounts of Mo-DCs were also inﬁltrated with
a higher amount of MHC-IIhigh M1-like TAMs, at the expense of
MHC-IIlow M2-like TAMs, suggesting that these differentiation
pathways employ overlapping signals25,26. In the case of Mo-DCs,
Flt3L and GM-CSFR appear both instrumental for their
differentiation, while MHC-IIhigh TAMs are inﬂuenced by
GM-CSFR42, but not Flt3L. The involvement of GM-CSFR in
the generation of tumour-associated Mo-DCs is remarkable,
as it disagrees with the GM-CSFR-independent generation of
inﬂammatory monocyte-derived DCs in infectious models of
acute inﬂammation17. This may be explained by the more
chronic, smoldering type of inﬂammation in the tumour
microenvironment, or, alternatively, Mo-DC generation may
depend on the presence of cDCs. In this scenario, Flt3L and GM-
CSFR would contribute to cDC generation, which subsequently
instruct monocyte-to-Mo-DC differentiation. Finally, the
presence of cDC1s and cDC2s seemed dependent on a
combination of both Flt3L and GM-CSFR signalling. In this
regard, it was previously shown that the combined loss of
GM-CSF and Flt3L generates a much greater decrease in cDCs
than the loss of Flt3L alone29.
Intracellular staining for IRF4 and IRF8 further corroborated
the heterogeneity of the TADC compartment. High levels of IRF8
were detected in tumour-associated cDC1s and of IRF4 in
tumour-associated cDC2s, suggesting their kinship to cDC1s and
cDC2s found in several organs, respectively30. IRF8 also regulates
the inﬂammatory proﬁle of M1 macrophages43, but inﬂammatory
Mo-DCs only express intermediate levels of IRF8, as well as IRF4,
suggestive of other transcription factor(s) stimulating Mo-DC
development.
It was previously described that TADCs differ at the functional
level at different phases of tumour growth7. Here we showed that
the relative proportions of distinct TADC subsets evolve during
tumour progression, which could at least partly explain a change
in function over time. Indeed, although all TADC subsets express
high levels of costimulatory molecules and intrinsically possess
the capacity to activate naive T cells in an MLR, Mo-DCs
outcompeted cDCs for antigen uptake, both in vitro and in vivo.
However, Mo-DCs sorted from LLC-OVA tumours were
inefﬁcient inducers of naive OVA-speciﬁc CD8þ and CD4þ
T-cell proliferation. In fact, they efﬁciently suppressed
polyclonally- or OVA-stimulated T-cell proliferation. This
could be linked to their tolerogenic IL-10high TIP-DC
phenotype and high production of immune suppressive
molecules, such as NO and the mitochondrial superoxide
anion. Moreover, Mo-DCs, unlike both cDC subsets, failed to
upregulate CCR7 in tumours. Hence, Mo-DCs efﬁciently
scavenge tumour antigen, but are unable to migrate to the
tdLN, and contribute to an immunosuppressive environment
at the tumour site.
Conversely, we could show that cDCs sorted from tdLNs of
LLC-OVA tumour-bearing mice could stimulate OVA-speciﬁc
CD8þ and CD4þ T-cell responses, indicative for in vivo
migration of antigen-loaded cDCs from the tumour to the tdLNs,
in line with the high CCR7 expression of these cells and as
recently shown in other models44. Notably, cDC2s, either isolated
from the tumour site or from tdLNs, were unique in their Th17-
inducing capacity, which is likely to be linked with their high
production of the Th17-inducing cytokines IL-23, IL-1b and IL-6.
The Th17-inducing capacity of this DC subset has also been
d6 d8 d10 d13 d15 d17
0
500
1,000
1,500
Days post B16-OVA inoculation
Tu
m
ou
r v
ol
um
e 
(m
m3
)
Non-vacc
Ova Vacc
cDC1 vacc
cDC2 vacc
***
****
****
***
****
Non-vacc cDC1 vacc cDC2 vacc
0
2
4
6
8
%
CD
8+
 T
 c
el
ls 
of
 to
ta
l t
um
ou
r
** **
a b
Figure 10 | cDC1 vaccination is more effective than cDC2 vaccination in B16 melanoma tumour-bearing mice. (a,b) Growth curve of B16-OVA tumours
(a) and percentages of CD8þ T cells in B16-OVA tumours (b) after vaccination with LLC-OVA TADC subsets following the protocol depicted in Fig. 8a.
n¼4–6 tumours. Statistical analysis by one-way ANOVA. **Po0.01; ***Po0.001; ****Po0.0001.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13720 ARTICLE
NATURE COMMUNICATIONS | 7:13720 | DOI: 10.1038/ncomms13720 | www.nature.com/naturecommunications 13
reported in the mucosa21,23. Hence, tumours contain both
suppressive Mo-DCs and fully functional, mature cDC subsets,
the latter being of interest for therapeutic purposes.
Throughout the past decade, the use of patient-derived DCs as
a means to elicit therapeutically relevant immune responses in
cancer patients has been extensively investigated. However, DCs
used for vaccination are commonly generated from peripheral
blood monocytes and might thus be reprogrammed by the
tumour microenvironment into suppressive Mo-DCs45,46. To
assess whether tumour-associated cDC subsets could be amenable
to elicit relevant immune memory responses in cancer, we
isolated these cells from LLC-OVA tumours to immunize mice,
without ex vivo stimulation or antigen loading of the sorted
tumour-derived cDCs, prior to a challenge with LLC-OVA or
B16-OVA. LLC tumours are heavily inﬁltrated by M2-oriented
TAMs, which are mainly recruited to hypoxic tumour areas and
prohibit anti-tumour immunity25,26. Reprogramming of these
macrophages, for example, by preventing their entry into hypoxic
sites has been shown to initiate a cascade of anti-tumour events
resulting in reduced tumour growth47. B16 tumours, on the other
hand, are poorly inﬁltrated by myeloid cells, whose contribution
to tumour growth is rather minor48. Interestingly, cDC2
vaccination led to a reduced LLC-OVA, but not B16-OVA,
tumour growth paralleled by an increased inﬁltration of RORgtþ
CD4þ T cells, a reduction of monocytic and granulocytic MDSCs
and a reprogramming of TAMs from a protumoral M2-like
MHC-IIlow to an antitumoral M1-like MHC-IIhigh phenotype.
Th17 cells are crucial for this antitumoral effect of cDC2
vaccination, but the exact downstream mechanisms still need
elucidation. The Th17-associated cytokine IL-21 was reported to
shift TAMs from M2-like to M1-like cells in breast tumours49,
but effects of IL-17 on TAM polarization were not reported.
Interestingly, GM-CSF was recently shown to regulate the M1-
like phenotype of TAMs50 and is coming to the forefront as a
Th17 signature cytokine51,52. Notably, cDC2 vaccination does not
increase the number of SIINFEKL-speciﬁc CTL in tumours
compared with non-vaccinated mice, but increases the IFNg
production by these cells, explaining the partial contribution of
CD8þ T cells to the success of vaccination. Interestingly, cDC2
vaccination does not signiﬁcantly inﬂuence B16-OVA tumour
growth, the control of which may be more strictly dependent on
OVA-speciﬁc CTLs. In agreement with the antitumoral immune
responses induced by cDC1s in melanomas53, our cDC1
vaccination increases the proportion of intratumoral CTLs
resulting in a signiﬁcant reduction of B16-OVA tumour
growth. The lack of effect on LLC-OVA tumours is likely due
to the dominance of immunosuppressive cell types, such as M2-
like TAMs and MDSCs, in the environment. The proposed
vaccination strategy holds promise as a beneﬁcial follow-up
therapy, where genuine tumour-derived cDCs could be sorted
from postoperative, primary tumour tissue. Of note, the absolute
number of TADCs required in our vaccination approach was very
low (104 cells) compared with similar reports applying DC
vaccination (with 105 to 3 106 cells), as either prophylactic or
therapeutic strategies54–57. Moreover, unlike most DC-based anti-
tumour approaches currently under investigation, knowledge of
the immunodominant tumour antigen is no prerequisite for this
TADC vaccination strategy.
In conclusion, we unraveled the coexistence of ontogenically
and functionally distinct TADC subsets, which can facilitate the
design of therapeutic interventions targeted at speciﬁc TADC
subsets. In particular, cDC1s are needed to boost anti-tumour
CTLs, which may not work efﬁciently in tumours dominated by
MDSCs and M2-oriented TAMs. In this case, cDC2s may help
in eliminating MDSCs and shifting the TAM phenotype from
M2-like to M1-like.
Methods
Mouse strains. Female Balb/c, CD45.2 and CD45.1 C57BL/6 mice were from
Janvier. Ubiquitin-GFP mice were purchased from Jackson. Csf2rb / , Flt3l / ,
Ccr2 / , Il23a / and MMTV-PyMT mice were provided by Melanie Greter
(University of Zurich, Germany), Bart Lambrecht (VIB-UGent, Belgium), Frank
Tacke (Aachen University, Germany), Ve´ronique Flamand (Universite´ Libre de
Bruxelles, Belgium) and Massimiliano Mazzone (VIB-KULeuven, Leuven,
Belgium) respectively.
All procedures followed the guidelines of the Belgian Council for Laboratory
Animal Science and were approved by the Ethical Committee for Animal
Experiments of the Vrije Universiteit Brussel (licenses 11-220-3 and 15-220-2).
Cell cultures and tumour models. LLC was purchased from the ATCC Cell
Biology Collection. The 3LL-R variant was generated in house by sequential
exposure of C57BL/6 Lewis Lung carcinoma (3LL cells) to LPS/LK-activated
peritoneal macrophages in vitro and correlated with resistance towards TNF-a and
an increased tumorigenicity on s.c. inoculation, while the 3LL-S variant represented
a clone from the parental 3LL, which in contrast was highly sensitive for macro-
phage-mediated cytotoxicity32. LLC-OVA, MC38, B16-OVA and T241 cells were
kind gifts from Dmitry Gabrilovich (The Wistar Institute, Philadelphia, USA),
Massimiliano Mazzone (VIB-KULeuven), Karine Breckpot (Vrije Universiteit
Brussel, Brussels, Belgium) and Lena Claesson-Welsh (University of Uppsala,
Uppsala, Sweden), respectively.
LLC-OVA, 3LL-R and 3LL-S cell lines were maintained in Roswell Park
Memorial Institute-1640 medium (RPMI; Sigma) supplemented with 10% (v/v)
heat-inactivated fetal calf serum (FCS; Gibco), 300 mgml 1 L-glutamine (Gibco),
100 unitsml 1 penicillin and 100mgml 1 streptomycin (Gibco) and monthly
tested for the presence of mycoplasma. For MC38, B16-OVA and T241 cultures,
RPMI was replaced by Dulbecco’s modiﬁed Eagle’s medium (Sigma).
LLC, LLC-OVA, 3LL-R, 3LL-S lung carcinoma cells, MC38 colon carcinoma
cells, B16-OVA melanoma cells and T241 ﬁcrosarcoma cells were harvested and
single-cell suspensions of 3 106 in 200ml of phosphate-buffered saline (PBS) were
injected subcutaneously into the right ﬂank of syngeneic 6- to 9-week-old female
C57Bl/6 mice. Female MMTV-PyMT mice developed mammary tumours
spontaneously.
For ex vivo TADC and T-cell cultures, this medium was supplemented
with 1mM non-essential amino acids (Invitrogen), 1mM sodium pyruvate
(Invitrogen) and 0.02mM 2-mercapto ethanol (Invitrogen).
For intrathoracic 3LL-R injections, 5 105 3LL-R carcinoma cells were
harvested and resuspended together with 25 mg Matrigel in 50ml PBS. Cell
suspensions were kept on ice until injection. Mice were anaesthetized and placed in
the left lateral decubitus position. One-millilitre tuberculin syringes with 30-gauge
hypodermic needles were used to inject the cell inoculum percutaneously into the
right lateral thorax, at the lateral dorsal axillary line, approximately 1.5 cm above
the lower rib line just below the inferior border of the scapula. The needle was
quickly advanced 6mm into the thorax and was quickly removed after the
injection. After tumour injection, the mouse was turned to the right lateral
decubitus position. At day 7, mice were killed and lung tissue and lung tumours
were removed.
For trans-anal rectal cancer injections, mice were anaesthetized with a 1/10
Nembutal dilution. The anal oriﬁce was gently enlarged with a blunt-tipped
forceps. In case of feces present, the colon was rinsed with saline using a ﬂexible
catheter. MC38 cells were injected submucosally into the distal posterior rectum at
concentrations of 2.5 105 per 50 ml PBS with a 29-gauge syringe. After the
injection, the syringe was kept in a position for a few seconds, to prevent back ﬂow.
After 4 weeks, mice were killed and tumours were carefully removed.
Tumour volumes were determined by caliper measurements and calculated
using the formula: V¼ p (d2D)/6, where d is the minor tumour axis and
D is the major tumour axis.
Lung cancer and colorectal cancer patients. We enrolled four non-small-cell
lung carcinoma (NSCLC) patients who were not subjected to neo-adjuvant
chemotherapy, including two males (68 and 67 years of age) with pT2aN1M0
(stage IIA) spinocellular carcinoma and cT1bN0M0 (stage IA) carcinoma and two
females (67 and 59 years of age) with pT2aN0M0 (stage IB) adenocarcinoma and
pT2aN1M0 (stage IIA) spinocellular carcinoma. The four colorectal cancer patients
enrolled were not subjected to chemotherapy and included three males (71and 62
years of age) with pT3N0 adenocarcinomas, one male (79 years of age) with stage I
T2M0N0 adenocarcinoma and one female (49 years of age) with stage IV
adenocarcinoma. All protocols were approved by the Ethics Committee of the
University Hospitals Gasthuisberg (Leuven, Belgium), and all subjects gave written
informed consent before study participation (licenses S50623 for NSCLC and
S58730 for CRC).
Ex vivo single-cell preparation. Subcutaneous, orthotopic or MMTV-PyMT
tumours were excised, cut in small pieces, treated with 10Uml 1 collagenase I,
400Uml 1 collagenase IV and 30Uml 1 DNaseI (Worthington) for 30min at
37 C, squashed and ﬁltered. Red blood cells were removed using erythrocyte lysis
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13720
14 NATURE COMMUNICATIONS | 7:13720 | DOI: 10.1038/ncomms13720 | www.nature.com/naturecommunications
buffer and density gradients (Axis-Shield) were used to remove debris and
dead cells.
Tumour-draining LNs were cut, dissociated with 10Uml 1 collagenase I,
400Uml 1 collagenase IV and 30UmL 1 DNaseI (Worthington) for 45min
at 37 C and ﬁltered.
Spleens were ﬂushed with 200Uml 1 collagenase III (Worthington) and left
for 30min at 37 C. Afterwards, spleens were ﬁltered and red blood cells were
removed using erythrocyte lysis buffer.
To purify DC subpopulations from tumour, spleen or LNs, CD11cþ cells were
MACS-enriched (anti-CD11c microbeads; Miltenyi) and sorted using BD
FACSAria II (BD Biosciences) according to the gating strategy in Fig. 1a,
Supplementary Fig. 6A or Supplementary Fig. 8A, respectively.
Bone marrow leukocytes were isolated through ﬂushing of tibia and femur.
The obtained cell suspensions were ﬁltered, and red blood cells were removed using
erythrocyte lysis buffer. To purify bone marrow monocytes, CD11bþ cells were
MACS-enriched (anti-CD11b microbeads; Miltenyi) before sorting.
Flow cytometry and cell sorting of mouse samples. Commercial antibodies
for cell surface stainings are listed in Supplementary Table 1. To prevent aspeciﬁc
binding, cells were pre-incubated with rat anti-mouse CD16/CD32 (clone 2.4G2;
BD Biosciences).
Normalized delta-Median Fluorescence Intensity (DMFI) was calculated as:
((MFI staining)-(MFI isotype staining))/(MFI staining). FACS data were acquired
using a BD FACSCanto II or LSRII (both from BD Biosciences) and analysed using
FlowJo (Tree Star, Inc.). To purify TADCs, cells were sorted using a BD FACSAria
II (BD Biosciences) from 9 to 15 pooled tumours.
Flow cytometry of lung cancer and colorectal cancer patients. Lung tumour
biopsies, healthy lung tissues or colorectal tumour biopsies were minced in RPMI
medium containing 0.1% collagenase type I, 0.2% dispase type I and DNase I
100Uml 1 (60min at 37 C), passed through a 19-gauge needle and passed
through a 70 and 40 mm cell strainer. After erythrocyte lysis, cells were resuspended
in FACS buffer (PBS containing 2% FBS and 2mM EDTA) and counted.
Fc receptors were blocked using Human Fc block reagent (Miltenyi) for 15min
at 4 C. After washing, samples were stained with biotinylated anti-BDCA-1
antibody (Miltenyi) (1/10) and ﬁxable viability dye eFluor506 (eBioscience) (1/200)
for 30’ at 4 C in the dark. Subsequently, samples were washed and stained with
FITC-labelled anti-CD3 (eBioscience) (1/50), anti-CD19 (BD Biosciences) (1/20)
and anti-CD56 (eBioscience) (1/10), PE-labelled anti-BDCA-2 (Miltenyi) (1/50),
PE-TexasRed-labelled anti-CD16 (Invitrogen) (1/100), PeCy7-labelled anti-CD11c
(1/10), AF700-labelled anti-CD45 (BD Biosciences) (1/20), APC-Cy7-labelled
anti-HLA-DR (eBioscience) (1/100), Paciﬁc Blue-labelled anti-CD14 (Invitrogen)
(1/100), BV605-labelled anti-CD11b (BD Biosciences) (1/200), APC-labelled anti-
BDCA-3 and BV786-labelled streptavidin (BD Biosciences) (1/200) for 300 at
4 C in the dark.
Samples were washed and ﬁxed for 450 at room temperature (RT) using
200ml of Fix/Perm per sample (FoxP3/Transcription factor staining buffer set;
eBioscience). Cells were washed twice in Perm buffer and stained with PerCP-
Cy5.5-labelled anti-IRF8 (eBioscience) (1/400) and unlabelled anti-IRF4 (Santa
Cruz) (1/400) for 300 at RT in the dark in Perm buffer with Human Fc block
reagent (Miltenyi) (1/20). After washing with Perm buffer, samples were stained
with AF647-conjugated donkey anti-goat (Molecular Probes, Carslbad, CA, USA)
(1/1000) for 300 at RT in the dark. Cells were washed with FACS buffer and
measured directly on a BD LSRII ﬂow cytometer (BD Biosciences) or kept
overnight at 4 C. FACS data were analysed using FlowJo (Tree Star, Inc.).
Adoptive pre-cDCs and monocyte transfers. Bone marrow Ly6Chi monocytes
and pre-cDCs were labelled with CellTrace Violet (Molecular Probes) and sorted
from CD45.2 mice. 106 Ly6Chi monocytes or 4 105 pre-cDCs were intravenously
injected in 3LL-R tumour-bearing CD45.1 mice. The fate of the CD45.2þ
CellTraceþ progeny was determined 72 h later.
Cell depletion experiments. CD4þ T cell, CD8þ T cell and NK(T) cells were
depleted during LLC-OVA tumour growth by intraperitoneal injection of 300 mg of
anti-CD4 (GK1.5), 200 mg of anti-CD8 (YTS169) or 300 mg of anti-NK1.1 (PK136),
respectively, every 2 to 3 days, starting 1 day prior to tumour inoculation.
In vitro Ag uptake and phagocytosis assays. For in vitro Ag uptake, freshly
isolated tumour single-cell suspensions were cultured in 96-well plates for 15min
at 4 or 37 C, in the presence of ovalbumin ﬂuorescently labelled with AF488
(Molecular Probes) at a ﬁnal concentration of 10 mgml 1. OVA uptake by
TADCs was assessed via ﬂow cytometry.
For in vitro latex uptake, freshly isolated tumour single-cell suspensions were
cultured in 96-well plates for 40min at 4 or 37 C, in the presence of latex
microspheres (Polysciences) diluted at 1:5,000. Latex uptake by TADCs was
assessed via ﬂow cytometry. For measuring in vivo latex uptake by TADCs,
tumour-bearing mice were injected intravenously with 250 ml of yellow-green latex
microspheres (Polysciences) diluted 1:25 in PBS. After 1–2 h, tumour single-cell
suspensions were made and latex uptake by TADC subpopulations was assessed via
ﬂow cytometry.
DQ-OVA processing experiments. To assess TADC antigen processing, tumour
single-cell suspensions were incubated for 15min at 0 or 37 C in the presence of
10 mgml 1 DQ-OVA (Molecular Probes), allowing antigen uptake. After thorough
washing, cells could further process DQ-OVA intracellularly during different time
intervals, at 0 or 37 C. Following each time interval, cells were surface labelled and
DQ-OVA ﬂuorescence in each subset was measured via ﬂow cytometry.
Mixed leukocyte reaction. For mixed leukocyte reaction assays, T cells were
puriﬁed from Balb/c splenocytes, by ﬁrst immunodepleting CD11cþ and CD19þ
cells using an MACS LD column with anti-CD11c and anti-CD19 microbeads
(Miltenyi Biotech) and subsequently positively selecting CD4þ or CD8þ T cells
using anti-CD4 or anti-CD8 microbeads (Miltenyi Biotech). 2 105 puriﬁed Balb/c
T cells were cultured in round-bottom 96-well plates with different concentrations
of TAM or TADC sorted from 13-day-old 3LL-R tumours or C57Bl/6 splenic
cDCs. Three days later, 3H-thymidine was added and cell proliferation was mea-
sured after another 18 h culture as counts per minute (c.p.m.) on a Wallac 1450
Liquid Scintillation Counter.
Suppression assays and OT-I and OT-II T-cell activation. For OT-I and OT-II
proliferation assays, MACS sorted CD11cCD19-CD11bCD4CD8þ OT-I
and CD11cCD19CD11bCD8CD4þ OT-II T cells were stained with
0.2 mM CFSE or 5 mM CellTrace Violet (Molecular Probes) following the manu-
facturer’s instructions and cultured in ﬂat-bottom 96-well plates. Puriﬁed TADCs
or splenic cDCs were added to 105 OT-I or OT-II T cells, which were stimulated
with 1 mgml 1 anti-CD3 and 2 mgml 1 CD28 as a positive control. In case of
antigen pulsing, 250 mgml 1 of OVA was added. To inhibit iNOS the co-cultures
were supplemented with 5 mM L-NMMA (NG-monomethyl-L-arginine; Alexis
Biochemicals). After 72 h of co-incubation, proliferation of T cells was measured
via CFSE dilution using ﬂow cytometry.
For suppression assays, Mo-DCs or MDSCs were sorted from 12-day-old 3LL-R
tumour single-cell suspensions and added at different ratios to splenocytes
stimulated 1 day earlier with anti-CD3 (1 mgml 1) and CD28 (2 mgml 1) and
cultured in ﬂat-bottom 96-well plates. After 18 h 3H-thymidine was added and
T-cell proliferation was measured after another 24 h of culture as c.p.m. on a
Wallac 1450 Liquid Scintillation Counter.
For restimmulation of T cells sorted from tdLNs, CD4þ and CD8þ T cells
were sorted from tdLN from 12-day-old LLC-OVA tumour-bearing mice. T cells
were stained with 5 mM CellTrace Violet (Molecular Probes) following the
manufacturer’s instructions and were cultured in ﬂat-bottom 96-well plates.
5 104 LLC-OVA-puriﬁed TADCs were added to 105 CD4þ or CD8þ T cells.
After 18 h, 3H-thymidine was added and T-cell proliferation was measured after
another 48 h of culture as c.p.m. on a Wallac 1450 Liquid Scintillation Counter.
Measurement of cytokine and chemokine production. Cytokine and chemokine
concentrations were measured by Bio-Plex (Bio-Rad), according to the supplier’s
protocols.
TADC vaccination experiments. For vaccination experiments, naive C57Bl/6
mice were subcutaneously injected with 104 TADCs of a speciﬁc subset, 6 and
3 weeks prior to subcutaneous LLC-OVA or B16-OVA inoculation. TADCs were
sorted from a pool of 10–12 LLC-OVA tumour-bearing mice. Mice vaccinated
subcutaneously with 100mg OVA protein in 100ml CFA were used as positive
controls.
RNA extraction and cDNA preparation for qPCR. RNA was extracted using
TRIzol (Invitrogen) and was reverse-transcribed with oligo(dT) and SuperScript II
RT (Invitrogen). Quantitative real-time PCR was performed in an iCycler, with iQ
SYBR Green Supermix (Bio-Rad). Primer sequences are listed in Supplementary
Table 2. PCR cycles consisted of 10 94 C, 4500 55 C, 10 72 C. Gene expression was
normalized using ribosomal protein S12 (Mrps12) as a housekeeping gene. Primers
are listed in Supplementary Table 2.
Statistics. Signiﬁcance was determined by the Student’s t-test or analysis of
variance followed by a post test using GraphPad Prism 6.0 software. A P-value
o0.05 was considered statistically signiﬁcant. All graphs show mean±s.e.m.
Data availability. Data supporting the ﬁndings of this study are available within
the article and its supplementary information ﬁles are from the corresponding
author upon reasonable request.
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